PINANE THROMBOXANE A₂ ANALOGUES ARE NON-SELECTIVE PROSTANOID ANTAGONISTS IN RAT AND HUMAN STOMACH MUSCLE

ALAN BENNETT & GARETH J. SANGER¹

Department of Surgery, King's College Hospital Medical School, London SE5 8RX

- 1 Pinane thromboxane A_2 (PTx A_2) and its epi-OH isomer were studied on rat and human stomach longitudinal muscle.
- 2 PTxA₂ $(0.5\mu g/ml)$ usually caused a slight contraction of rat gastric fundus. Contractions to PGE₂, PGF_{2x}, PGI₂ and expoxymethano analogues of PGH₂ (U-46619 and U-44069) were substantially inhibited, whereas those to PGD₂ and acetylcholine were only slightly reduced.
- 3 In human stomach, $PTxA_2 0.5 \mu g/ml$ rarely stimulated the muscle. Contractions to PGE_2 , $PGF_{2\alpha}$ and U-46619 were antagonized, with little effect on those to acetylcholine.
- 4 epi-PTxA₂ $(0.5 \,\mu\text{g/ml})$ did not affect rat gastric tone. It was moderately potent against PGI₂ on rat gastric fundus, but was less effective than PTxA₂ against U-44069.

Introduction

The pinane analogue of thromboxane A_2 (PTxA₂; Figure 1) antagonizes vasoconstriction caused by azo or epoxymethano analogues of prostaglandin H₂ (PGH₂), but its potency may vary with the blood vessel used (Nicolaou, Magolda, Aharony, Smith & Lefer, 1979; Aharony, Smith, Lefer, Magolda & Nicolaou, 1980; Ansell, Caton, Palfreyman, Stuttle, Tuffin & Walker, 1980). This finding is consistent with the expectation that PTxA2 might act on thromboxane receptors, since the analogues of PGH₂ mimic the action of thromboxane A₂ (Coleman, Humphrey, Kennedy, Levy & Lumley, 1980). Evidence of selectivity was provided by the failure of the analogue to antagonize inhibition of platelet aggregation caused by PGD₂ or PGI₂, in contrast to PTxA₂'s antagonism of platelet aggregation caused by PGH₂ analogues (Nicolaou et al., 1979; Aharony et al., 1980).

We have now tested PTxA₂ and its epi-OH stereoisomer (epi-PTxA₂; Figure 1) as prostanoid antagonists in longitudinal muscle strips of rat and human stomach. All the prostanoids tested contract these tissues, except for PGI₂ which relaxes the longitudinal muscle of human stomach (see Bennett, Jarosik, Sanger & Wilson, 1980; Bennett & Sanger, 1980; Bennett, Hensby, Sanger & Stamford, 1981). The results show that although the pinane thromboxane analogues antagonize substances thought to be thromboxane mimetics, they also block responses to other prostanoids.

¹Present address: Beecham Laboratories, Harlow, Essex.

а




Figure 1 Structures of the pinane thromboxane A₂ (PTxA₂) isomers. (a) PTxA₂; (b) epi-PTxA₂, which are respectively 7((1S, 2R, 3R, 5S)-(3-(3S, 3-hydroxyoct-trans-1-enyl)-6,6-dimethyl-bicyclo (3.1.1) hept-2-yl) hept-5-cis-enoic acid, and 7((1S, 2R, 3R, 5S)-(3-(3R, 3-hydroxyoct-trans-1-enyl)-6,6-dimethylbicyclo (3.1.1) hept-2-yl) hept-5-cis-enoic acid.

Methods

Rat stomach

Adult Wistar rats of either sex were stunned and bled. Strips of gastric fundus approximately 2 cm long and 3 mm wide were cut parallel to the longitudinal muscle fibres, one from each side of the greater curvature. These were suspended under a 1 g load in 10 ml tissue baths containing Krebs solution (NaCl 7.1, CaCl₂ 6H₂O 0.55, KH₂PO₄ 0.16, KCl 0.35,

MgSO₄ 7H₂O 0.29, NaHCO₃ 2.1 and dextrose 1.0 g l^{-1}). The solution was maintained at 37°C and bubbled with 5% CO₂ in O₂. Isotonic muscle contractions were recorded with transducers and pen recorders, using magnifications of 8–16.

In each experiment, cumulative dose-response curves were obtained to one prostanoid and to acetylcholine (ACh), with 2 min intervals between each cumulative addition. A PTxA2 isomer was then added to the bathing solution, and at 10 min intervals submaximal contractions to a single dose of ACh were obtained (30s contact; pinane analogue replaced after each washout). After approximately 1 h, a time chosen arbitrarily to allow equilibration of the analogue with the tissue so that the effect would be near-maximal during each cumulative dose-response determination, responses to each agonist were redetermined. Measurements were made of the maximum response and of the concentration of agonist required to give a contraction 50% of maximum $(EC_{50}).$

Human stomach

Macroscopically normal specimens of human stomach, at least 6 cm from any lesion, were obtained at operation for benign or malignant disease. The mucosa and submucosa were cut away, and strips 2 to 3 cm long and 4 to 5 mm wide were cut parallel to the longitudinal muscle fibres. They were placed in Krebs solution equilibrated with 5% $\rm CO_2$ in $\rm O_2$ and studied the same day or after overnight storage at $\rm 4^{\circ}C$.

Human stomach strips were suspended in tissue baths, as described for the rat stomach. After obtaining rough dose-response curves to ACh and to one prostanoid, doses were chosen which gave approximately equal consistent submaximal responses for each substance. Contact times were 30 s; cycle times were 10 min except when repeated washing for up to 30 min was necessary to restore resting tone after a dose of prostanoid. PTxA₂ was then added to the bath and consistent responses again obtained to ACh, and the prostanoid was then tested. The interval between adding PTxA2 and the prostanoid was 30-40 min. Contractions or relaxations were expressed as a percentage of pre-PTxA2 controls (mean of two or three preceding responses). In addition, the degree of block was assessed where possible by determining the increase in the dose of agonist needed to restore the response (dose-ratio).




Figure 2 Cumulative dose-responses of rat gastric fundus to acetylcholine (ACh) and prostacyclin (PGI₂) alone (top traces) or in the presence of pinane thromboxane A_2 (PTxA₂) $0.5 \,\mu\text{g ml}^{-1}$ (bottom traces). The concentrations of agonists were increased 10 fold at each dot, unless shown otherwise; n and μ represent ng and μ g ml⁻¹ bathing fluid. PTxA₂ caused a slight contraction of rat gastric fundus. It reduced the response to PGI₂ but had little effect on ACh. Horizontal bar 5 min; vertical bar 5 cm.




Figure 3 Cumulative dose-responses of rat gastric fundus to acetylcholine (ACh) and U-46619 alone (top traces) or in the presence of pinane tromboxane A_2 (PTxA₂) $0.5 \,\mu \mathrm{g} \,\mathrm{ml}^{-1}$ (bottom traces). The concentrations of agonists were increased 10 fold at each dot, unless shown otherwise; n and μ represent ng and $\mu \mathrm{g} \,\mathrm{ml}^{-1}$ bathing fluid. PTxA₂ caused a slight contraction of rat gastric fundus. It reduced the response to U-46619 but had little effect on ACh. Horizontal bar 5 min; vertical bar 5 cm.

Drugs

The following were used: acetylcholine perchlorate, PGD₂, PGE₂, PGF_{2 α} tromethamine salt, sodium PGI₂, (15S)-hydroxy-9 α , 11 α and (15S)-hydroxy-11 α , 9 α (epoxymethano) prosta-5Z, 13E-dienoic acids (U-44069 and U-46619 respectively), PTxA₂ and epi-PTxA₂ (May and Baker Ltd, see Figure 1). All concentrations refer to the acid or salt listed above.

Sodium PGI_2 was dissolved in 1M Tris buffer (5 mg PGI_2 ml⁻¹) and freshly diluted further with 50 mM Tris buffer adjusted to pH 7.9 with 1M HCl. U-44069 and U-46619 were dissolved in ethanol (10 mg ml^{-1}), diluted to 0.1 mg ml^{-1} with 0.9% w/v NaCl solution (saline) and then further diluted with Krebs solution. Other prostanoids were dissolved in ethanol (5 or 10 mg ml^{-1}) and diluted with saline. $PTxA_2$ isomers were dissolved in ethanol (5 mg ml⁻¹) and diluted with saline. Acetylcholine was dissolved in saline.

Vehicle controls had little or no effect on muscle tone, except that those for high concentrations of PGI₂ usually caused weak contraction of rat stomach. Results are given as medians with ranges or semi-quartile ranges in parentheses, and analysed using the Wilcoxon matched-pairs test or the Mann-Whitney U-test.

Results

Rat stomach

The concentrations of PTxA₂ chosen for these experiments $(0.5\mu g\,\text{ml}^{-1})$ was reported by Nicolaou *et al.* (1979) to be well below the concentration required for inhibition of thromboxane synthesis in washed rabbit platelets $(3.7-37\,\mu g\,\text{ml}^{-1})$. PTxA₂ $0.5\,\mu g\,\text{ml}^{-1}$ usually caused a weak contraction of rat stomach muscle which was slow in onset but sustained while PTxA₂ was present (Figures 2 and 3). In two experiments, incubation for at least 90 min with hyoscine, mepyramine, methysergide, phenoxybenzamine, and pronethalol $(0.2, 0.2, 0.1, 0.5 \,\text{and}\, 1\,\mu g\,\text{ml}^{-1}$ respectively) slightly reduced the muscle tone but did not greatly affect the contraction to PTxA₂(0.5 $\mu g\,\text{ml}^{-1}$ for 10 min).

ACh, PGD₂, PGE₂, PGF_{2 α}, PGI₂, U-46619 and U-44069 each caused muscle contraction. Their respective median EC₅₀ values were 39, 270, 1.1, 21, 19, 9.6 and 16 ng/ml, in broad agreement with our earlier findings (Bennett *et al.*, 1980).

In the presence of PTxA₂ (0.5 μ g ml⁻¹) the maximum contraction to ACh or the prostanoids was less, probably because of the additional contraction to PTxA₂, since the overall maximum muscle shortening was unaffected. Contractions to PGE₂, PGF_{2α},




Figure 4 Antagonism by pinane thromboxane A_2 (PTxA₂) or epi-PTxA₂ of submaximal contractions to prostanoids in rat isolated stomach muscle. Results are expressed as the multiple increased in EC₅₀ after addition of a pinane isomer, and are given as columns representing medians, with semiquartile ranges shown as numbers above and below the medians, D₂, E₂, F₂, I₂, U19 and U69 are prostaglandins D₂, E₂, F₂, U-46619 and U-44069 respectively. The effect of the isomers on each prostanoid are compared with that on acetylcholine (ACh); **P<0.05; ***P<0.01; n=number of experiments.

PGI₂ and the epoxymethano analogues of PGH₂ were inhibited with PTxA₂, as shown for PGI₂ and U-46619 in Figures 2 and 3, and by the increase in EC₅₀ values (Figure 4). In contrast, contractions to PGD₂ were not reduced more than the small extent seen with ACh (Figure 4).

Epi-PTxA₂ (0.5 or $1.5 \,\mu\mathrm{g}\,\mathrm{ml}^{-1}$) did not affect the tone of rat isolated gastric fundus. The only prostanoids tested were PGI₂ and the epoxymethano analogues of PGH₂, since they were most susceptible to PTxA₂. Contractions to them were antagonized by epi-PTxA₂ more than were contractions to ACh (Figure 2). Overall, the epi-isomer was less effective than PTxA₂, but this was statistically significant (P<0.05) only with ACh and U-44069. Raising the concentration of epi-PTxA₂ to 1.5 μg ml⁻¹ increased the antagonism to the PGH₂ analogues and, to some extent, of ACh (Figure 4).

Human stomach

The effects of PTxA₂ were studied on 10 longitudinal stomach muscle strips, taken from 4 patients (3 with cancer and one with persistent prepyloric ulcer; 3 female, 1 male; 62-67 years). PTxA₂ 0.5 µg ml⁻¹ usually had no effect on muscle tone, except for a

slow increase in 2 out of 4 strips from one patient.

PTxA₂ $0.5 \mu g \, \text{ml}^{-1}$ had little effect on submaximal contractions to ACh (1 to $20 \, \mu g \, \text{ml}^{-1}$), but somewhat reduced contractions to PGE₂ (0.5 or $1 \, \mu g \, \text{ml}^{-1}$), PGF_{2 α} (1 or $5 \, \mu g \, \text{ml}^{-1}$) or U-46619 (0.01 to $1 \, \mu g \, \text{ml}^{-1}$); relaxations to PGI₂ (1 or $2 \, \mu g \, \text{ml}^{-1}$) were not greatly altered. Figure 5 shows the results for ACh, U-46619 and PGF_{2 α}, and Table 1 shows all the results. The effect of PTxA₂ on contractions to PGD₂ was not studied, since the longitudinal muscle of human isolated stomach usually contracts only weakly to this prostanoid (Bennett *et al.*, 1981). No studies were made with epi-PTxA₂.

Discussion

Nicolaou et al. (1979) and Aharony et al. (1980) found that PTxA₂ potently antagonized constriction of cat coronary artery and aggregation of human platelets induced by PGH₂ analogues. Since the drug did not affect the inhibition of platelet aggregation by PGD₂ or PGI₂, this might reflect the finding in smooth muscle that antagonists of prostaglandin excitatory effects do not block inhibitory effects (Bennett, 1974; Sanner & Eakins, 1976). The potency of






Figure 5 Responses of human gastric longitudinal muscle. Top trace U-46619 (U, $0.1 \,\mu\mathrm{g}\,\mathrm{ml}^{-1}$). Bottom trace prostaglandin $F_{2\alpha}$ (PGF_{2\alpha}, F, 5 $\mu\mathrm{g}\,\mathrm{ml}^{-1}$), Both traces, unlabelled contractions are ACh 10 $\mu\mathrm{g}\,\mathrm{ml}^{-1}$; w = drug washed from bath. PTxA₂ 0.5 $\mu\mathrm{g}\,\mathrm{ml}^{-1}$ reduced responses to U-46619 and PGF_{2\alpha}, with little effect on those to acetylcholine. Horizontal bar 30 min; vertical bar 5 cm.

PTxA₂ and its epi-isomer may vary with the vascular muscle or the agonist used. Ansell *et al.* (1980) obtained a slight stimulation of rabbit aorta and mesenteric artery, and a weak antagonism of the TxA₂-like material released from guinea-pig lung. In these arterial tissues both thromboxane analogues were partial agonists, but we obtained weak excitation only with PTxA₂, whereas both isomers inhibited contractions to various prostanoids.

Epoxymethano analogues of PGH₂ are thought to act on thromboxane receptors (Coleman *et al.*, 1980), and PTxA₂ 0.5 μg ml⁻¹ did antagonize submaximal contractions of rat stomach to these analogues. However, the effect was not selective, since contractions to PGE₂, PGF_{2α}, PGI₂ and, to a lesser extent ACh, were also reduced. The findings with the longitudinal muscle of human stomach were similar to those with rat stomach, except that PGI₂

relaxes the human tissue and this response seemed unaffected by PTxA₂.

Other drugs besides PTxA2 have been reported to antagonize aggregation of blood platelets with arachidonic acid, PGH₂ or analogues of PGH₂, but so far there are no data on antagonism of other prostanoids which cause excitatory responses in other tissues. These antagonists include monocylic prostaglandin endoperoxides (Menzel, Roycroft, Nixon, Isaac & Porter, 1977), 13-aza-prostanoic acid (Le Breton, Venton, Enke & Halushka, 1979), carbocyclic TxA2 (Lefer, Smith, Araki, Smith, Aharony. Claremon, Magolda & Nicolaou, 1980) and 7oxabicyclo (2.2.1) heptane prostaglandin analogues (Sprague, Heikes, Harris & Greenberg, 1980). Of these compounds, only 13-aza-prostanoic acid was tested against PGE₁- or PGI₂-induced inhibition of platelet aggregation, where it was ineffective as an

Table 1 Effects of pinane thromboxane A_2 on the reaction of human stomach to acetylcholine (ACh) and prostanoids

	Response	% control	n	Dose-ratio
ACh	Contraction	93(56-110)	8	_
PGE_2	Contraction	74(70-78)	2	4
PGF _{2a}	Contraction	34(31-36)	2	>10
U-46619	Contraction	32(25-63)	4	>10
PGI_2	Relaxation	93(86–100)	2	-

PTxA₂ (0.5 μ g mI⁻¹) had little effect on submaximal contraction to ACh or relaxation to PGI₂, but inhibited contractions to the other prostanoids. % control shows medians with the ranges in parentheses. n = number of experiments. The dose-ratios are results of single experiments.

antagonist (Le Breton et al., 1979).

Nicolaou et al. (1979) found that epi-PTxA₂ was less potent than PTxA₂ as an antagonist of platelet aggregation. We obtained a similar potency relationship in rat stomach but, unlike PTxA₂, the epicompound had the advantage of not causing contraction, perhaps due to the unnatural 15-hydroxy configuration (Fried, Santhanakrishnan, Himizu, Lin, Ford, Rubin & Grigas, 1969; Tolman, Partridge & Barris, 1977; Birnbaum & Tolman, 1979). Since the block of contractions to PGI₂ in rat stomach by both pinane isomers was substantial, and evidence with the prostaglandin antagonist SC-19220 suggests that

PGI₂ and PGH₂ analogues act at different receptors in rat fundus (Bennett *et al.*, 1980), neither PTxA₂ nor epi-PTxA₂ are selective thromboxane antagonists. However, PTxA₂ and epi-PTxA₂ do not block responses to all excitatory prostanoids, as shown by the weak effect on PGD₂.

We thank the MRC for support, May & Baker Ltd for the PTxA₂ and epi-PTxA₂, the Upjohn Co. Ltd and the Wellcome Research Laboratories for prostanoids, and the Rayne Research Institute for providing the research accommodation.

References

- AHARONY, D., SMITH, J.N., SMITH, E.F., LEFER, A.M., MAGOLDA, R.L. & NICOLAOU, K.D. (1980). Pinane thromboxane A₂: a TxA₂ antagonist with antithrombotic properties. In Adv Prostaglandin & Thromboxane Res., Vol. 6. ed Samuelsson, B., Ramwell, P.W., & Paoletti, R. pp. 489-492. New York: Raven Press.
- ANSELL, M.F., CATON, M.P.L., PALFREYMAN, M.N., STUT-TLE, K.A.J., TUFFIN, D.P. & WALKER, J.L. (1980). A structural analogue of thromboxane A₂. In *Adv Prostaglandin & Thromboxane Res*, Vol. 6. ed Samuelsson, B., Ramwell, P.W., & Paoletti, R. pp. 485-487. New York: Raven Press.
- BENNETT, A. (1974). Prostaglandin antagonists. *Adv. Drug Res.*, **8**, 83–118.
- BENNETT, A., HENSBY, C.N., SANGER, G.J. & STAMFORD, I.F. (1981). Metabolites of arachidonic acid formed by human gastrointestinal tissues and their actions on the muscle layers. *Br. J. Pharmac.*, 74, 435-454.
- BENNETT, A., JAROSIK, C., SANGER, G.J. & WILSON, D.E. (1980). Antagonism of prostanoid-induced contractions of rat gastric fundus muscle by SC-19220, sodium meclofenamate, indomethacin or trimethoquinol. *Br. J. Pharmac.* 71, 169-175.
- BENNETT, A. & SANGER, G.J. (1980). Prostacyclin relaxes the longitudinal muscle of human isolated stomach and antagonizes contractions to some prostanoids. *J. Physiol*; **298**, 45–46P.
- BIRNBAUM, J.E. & TOLMAN, E.L. (1979). Prostaglandin E antagonist activity of 11-deoxy-16, 16-trimethylene prostaglandin E₁. *Prostaglandins*, **18**, 349-357.
- COLEMAN, R.A., HUMPHREY, P.P.A., KENNEDY, I., LEVY, G.P. & LUMLEY, P. (1980). U-46619, a selective thromboxane A₂-like agonist? *Br. J. Pharmac.*, **68**, 127-128P.
- FRIED, J., SANTHANAKRISHNAN, T.S., HIMIZU, J., LIN, C.H., FORD, S.H., RUBIN, B. & GRIGAS, E.O. (1969). Prostaglandin antagonists, synthesis and smooth muscle activity. *Nature*, 223, 208–210.

- LE BRETON, G.C., VENTON, D.L., ENKE, S.E. & HALUSHKA, P.V. (1979). 13-Aza prostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. *Proc. natn. Acad. Sci., U.S.A.*, **76**, 4097-4101.
- LEFER, A.M., SMITH, E.F., ARAKI, M., SMITH, J.B., AHARONY, D., CLAREMON, D.A., MAGOLDA, R.L. & NICOLAOU, K.C. (1980). Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A₂, a stable analog of thromboxane A₂. Proc. natn. Acad. Sci. U.S.A., 77, 1706–1710.
- MENZEL, D.B., ROYCROFT, J.H., NIXON, J.R., ISAAC, S.R. & PORTER, N.A. (1977). Inhibition of arachidonic acid and prostaglandin endoperoxide analog initiated human platelet aggregation by monocyclic endoperoxides. *Fedn Proc.*, **36**, 309.
- NICOLAOU, K.C., MAGOLDA, R.L., SMITH, J.B., AHARONY, D., SMITH, E.F. & LEFER, A.M. (1979). Synthesis and biological properties of pinane thromboxane A₂, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. *Proc. natn. Acad. Sci. U.S.A.*, 76, 2566–2570.
- SANNER, J.H. & EAKINS, K.E. (1976). Prostaglandin antagonists. In *Prostaglandins: Chemical & Biochemical Aspects.* ed Karim, S.M.M. pp. 139-190. Lancaster: MTP Press Ltd.
- SPRAGUE, P.W., HEIKES, J.E., HARRIS, D.N. & GREEN-BERG, R. (1980). Stereo-controlled synthesis of 7-oxabicyclo (2.2.1) heptane prostaglandin analogs as thromboxane A₂ antagonists. In Adv. Prostaglandin and Thromboxane Res. Vol. 6. ed. Samuelsson, B., Ramwell, P.W., & Paoletti, R. pp. 493–496. New York: Raven Press.
- TOLMAN, E.L., PARTRIDGE, R. & BARRIS, E.T. (1977). Prostaglandin E antagonist activity of 11,15-bisdeoxy prostaglandin E₁ and congeners. *Prostaglandins*, **14**, 11-19.

(Received February 1, 1982. Revised June 23, 1982.)